Kisunla Got a Canadian Recommendation. A Drug Bill Did Not.

CNBC reported on Monday that Canada's Drug Agency on Friday welcomed a positive recommendation to reimburse Kisunla for eligible adults. That is not a U.S. price cut, and it does not show that a Canadian plan has started paying.

Kisunla is Eli Lilly's treatment for early Alzheimer's. Lilly shares were nearly 2% higher in early Monday trading after the report. A positive recommendation can matter later if public drug plans adopt it and set what a patient pays. The brief gave no start date, copay, or list price in Canada or the United States.

The Friday decision and the Monday report are different steps. Neither one is a filled prescription. The share move shows how traders reacted; it is not a pharmacy receipt.

Did the Kisunla recommendation lower a prescription bill? No price cut was announced. Monday's report describes Friday's positive Canadian reimbursement recommendation for eligible adults, not a new U.S. or Canadian bill.